The Board of Directors of Moberg Pharma has resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders of approximately SEK 121 million before transaction costs.
The Rights Issue is conditional upon approval at an extraordinary general meeting, states the company.
“The financing we have secured gives us the opportunity to fully exploit MOB-015’s potential, both through the registration activities and launch preparations in Europe and an additional clinical study for the US market. The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma.
The company intends to use the net proceeds to finance registration activities and clinical work for MOB-015 as well as preparations for launch in Europe in 2023.
Photo of Anna Ljung: Moberg Pharma